Clinical trial
Pharmacogenetics as a Predictor of Toxicity in Pre-Menopausal Women Receiving…
NCT00352872 · Indiana University School of Medicine, Other · Terminated
Key facts
| NCT number | NCT00352872 |
|---|---|
| Title | Pharmacogenetics as a Predictor of Toxicity in Pre-Menopausal Women Receiving Doxorubicin and Cyclophosphamide in Early Breast Cancer |
| Official title | A Pilot Study of Cytochrome P450 Pharmacogenetics as a Predictor of Toxicity in Pre-Menopausal Women Receiving Doxorubicin and Cyclophosphamide in Early Breast Cancer |
| Lead sponsor | Indiana University School of Medicine, Other |
| Status | Terminated |
| Study type | Observational |
| Conditions | Breast Cancer |
| Enrollment | 23 |
| Start date | Feb 1, 2005 |
| Primary completion | Jan 13, 2009 |
| Completion | Jan 13, 2009 |
| First posted | Jul 17, 2006 |
| Last update posted | Mar 2, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: